Cargando…
Neurological Immunotoxicity from Cancer Treatment
The emergence of immune-based treatments for cancer has led to a growing field dedicated to understanding and managing iatrogenic immunotoxicities that arise from these agents. Immune-related adverse events (irAEs) can develop as isolated events or as toxicities affecting multiple body systems. In p...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268562/ https://www.ncbi.nlm.nih.gov/pubmed/34201529 http://dx.doi.org/10.3390/ijms22136716 |
_version_ | 1783720384659456000 |
---|---|
author | Wesley, Sarah F. Haggiagi, Aya Thakur, Kiran T. De Jager, Philip L. |
author_facet | Wesley, Sarah F. Haggiagi, Aya Thakur, Kiran T. De Jager, Philip L. |
author_sort | Wesley, Sarah F. |
collection | PubMed |
description | The emergence of immune-based treatments for cancer has led to a growing field dedicated to understanding and managing iatrogenic immunotoxicities that arise from these agents. Immune-related adverse events (irAEs) can develop as isolated events or as toxicities affecting multiple body systems. In particular, this review details the neurological irAEs from immune checkpoint inhibitors (ICI) and chimeric antigen receptor (CAR) T cell immunotherapies. The recognition and treatment of neurological irAEs has variable success, depending on the severity and nature of the neurological involvement. Understanding the involved mechanisms, predicting those at higher risk for irAEs, and establishing safety parameters for resuming cancer immunotherapies after irAEs are all important fields of ongoing research. |
format | Online Article Text |
id | pubmed-8268562 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82685622021-07-10 Neurological Immunotoxicity from Cancer Treatment Wesley, Sarah F. Haggiagi, Aya Thakur, Kiran T. De Jager, Philip L. Int J Mol Sci Review The emergence of immune-based treatments for cancer has led to a growing field dedicated to understanding and managing iatrogenic immunotoxicities that arise from these agents. Immune-related adverse events (irAEs) can develop as isolated events or as toxicities affecting multiple body systems. In particular, this review details the neurological irAEs from immune checkpoint inhibitors (ICI) and chimeric antigen receptor (CAR) T cell immunotherapies. The recognition and treatment of neurological irAEs has variable success, depending on the severity and nature of the neurological involvement. Understanding the involved mechanisms, predicting those at higher risk for irAEs, and establishing safety parameters for resuming cancer immunotherapies after irAEs are all important fields of ongoing research. MDPI 2021-06-23 /pmc/articles/PMC8268562/ /pubmed/34201529 http://dx.doi.org/10.3390/ijms22136716 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Wesley, Sarah F. Haggiagi, Aya Thakur, Kiran T. De Jager, Philip L. Neurological Immunotoxicity from Cancer Treatment |
title | Neurological Immunotoxicity from Cancer Treatment |
title_full | Neurological Immunotoxicity from Cancer Treatment |
title_fullStr | Neurological Immunotoxicity from Cancer Treatment |
title_full_unstemmed | Neurological Immunotoxicity from Cancer Treatment |
title_short | Neurological Immunotoxicity from Cancer Treatment |
title_sort | neurological immunotoxicity from cancer treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268562/ https://www.ncbi.nlm.nih.gov/pubmed/34201529 http://dx.doi.org/10.3390/ijms22136716 |
work_keys_str_mv | AT wesleysarahf neurologicalimmunotoxicityfromcancertreatment AT haggiagiaya neurologicalimmunotoxicityfromcancertreatment AT thakurkirant neurologicalimmunotoxicityfromcancertreatment AT dejagerphilipl neurologicalimmunotoxicityfromcancertreatment |